William M. Brown

October 17, 2026

3M to challenge $1.4B Australian PFAS lawsuit ahead of Q3 earnings. 3M is preparing to challenge Australia's $1.4 billion PFAS contamination lawsuit, a major legal development for the company. At the same time, market participants are looking ahead to 3M's upcoming third-quarter earnings, with Wall Street projections offering insights into key metrics. The stock is currently trading within its 52-week range, with an average analyst target of $186.15.

October 17, 2026

BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.

October 9, 2026

Celanese Sets Q3 Earnings Call for November 3, 2026. Celanese has announced it will hold its third-quarter earnings conference call on November 3, 2026. The company is also mentioned in a new industry report on thermo compression forming, which highlights its role in advanced manufacturing. With the stock trading near its 52-week low, upcoming earnings results may provide clarity on the company's performance.

October 17, 2026

L3Harris Faces Analyst Target Cuts Amid Defense Sector Volatility. Recent analyst notes show shifting price targets for L3Harris, with firms lowering estimates amid broader defense sector pressures. While sector-wide stock declines have created headwinds, the company's ongoing R&D investments remain a focal point for technology innovation. The varying analyst targets highlight current market uncertainty surrounding major defense contractors.